BANGALORE, Inde et HYDERABAD, Inde–(BUSINESS WIRE)–Pandorum Technologies, une société de médecine régénérative au stade clinique qui développe une plateforme de nouvelle génération pour la régénération tissulaire programmable, a annoncé aujourd’hui u…
Author: Business Wire
Pandorum Technologies und Nucelion Therapeutics geben strategische Zusammenarbeit in APAC-Märkten bekannt, um exosom-basierte Therapie zur Geweberegeneration bei Augenerkrankungen zu entwickeln
BANGALORE, Indien und HYDERABAD, Indien–(BUSINESS WIRE)–Pandorum Technologies, ein Unternehmen für regenerative Medizin im klinischen Stadium, das eine Plattform der nächsten Generation für programmierbare Geweberegeneration aufbaut, gab heute eine s…
Samenvatting: Pandorum Technologies en Nucelion Therapeutics kondigen strategische samenwerking aan voor productie van op exosomen gebaseerde weefselregeneratieve therapie voor oogziekten in APAC-markten
BANGALORE, India & HYDERABAD, India–(BUSINESS WIRE)–Pandorum Technologies, een bedrijf in de klinische fase van regeneratieve geneeskunde dat een platform van de volgende generatie ontwikkelt voor programmeerbare weefselregeneratie, heeft vandaag een…
Riassunto: Pandorum Technologies e Nucelion Therapeutics annunciano una collaborazione strategica imperniata sulla produzione di una terapia rigenerativa dei tessuti basata su esosomi mirata alle patologie oculari nei mercati APAC
BANGALORE, India, e HYDERABAD, India–(BUSINESS WIRE)–Pandorum Technologies, specialista della medicina rigenerativa in fase clinica impegnato nello sviluppo di una piattaforma di nuova generazione per la rigenerazione programmabile dei tessuti, oggi …
Resumen: Pandorum Technologies y Nucelion Therapeutics anuncian una colaboración estratégica para elaborar una terapia regenerativa de tejidos con base en exosomas para enfermedades oculares en mercados de APAC
BANGALORE (India) e HYDERABAD (India)–(BUSINESS WIRE)–Pandorum Technologies, una empresa de medicina regenerativa de fase clínica que está diseñando una plataforma de próxima generación para regeneración de tejidos programable, anunció hoy una colabo…
Alcon Terminates Agreement to Acquire STAAR Surgical
GENEVA–(BUSINESS WIRE)–Alcon Terminates Agreement to Acquire STAAR Surgical
National Vision Announces Participation in the 2026 ICR Conference
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that the Company is scheduled to present at the 2026 ICR Conference on Tuesday, January 13, 2026, at 9:00 a.m. Eastern Time….
SpliceBio nombra a Don Muñoz director financiero
BARCELONA–(BUSINESS WIRE)–SpliceBio, una empresa de medicamentos genéticos en fase clínica pionera en el empalme de proteínas para tratar enfermedades causadas por mutaciones en genes grandes, ha anunciado hoy el nombramiento de Don Muñoz como direct…
STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on preliminary estimates …
Lions World Vision Institute Advances Accessible Care with Vision Health Center Groundbreaking in Ybor City
TAMPA, Fla.–(BUSINESS WIRE)–Lions World Vision Institute (LWVI) broke ground on its new $16 million Vision Health Center in Tampa’s historic Ybor City.
SpliceBio Appoints Don Munoz as Chief Financial Officer
BARCELONA–(BUSINESS WIRE)–SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced the appointment of Don Munoz as Chief Financial Officer. Mr. Munoz, wh…
Ikarovec to Advance Pipeline With Exclusive Worldwide Option to VectorBuilder’s Intravitreal Capsid Technology
NORWICH, England & CHICAGO–(BUSINESS WIRE)– #BioTechNews–Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an ex…
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundat…
Samsung Bioepis beginnt mit der Vermarktung von BYOOVIZ®, einem Biosimilar zu Lucentis (Ranibizumab), in Europa
INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. gab heute bekannt, dass das Unternehmen mit der direkten Vermarktung von BYOOVIZ®, einem Biosimilar zu Lucentis1 (Ranibizumab), in Europa begonnen hat. Samsung Bioepis hat daran gearbeitet, ein…
Resumen: Samsung Bioepis inicia la comercialización de BYOOVIZ®, biosimilar de Lucentis (ranibizumab) en Europa
INCHEON, Corea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. acaba de anunciar que la empresa ha iniciado la comercialización directa de BYOOVIZ®, un biosimilar de Lucentis1 (ranibizumab) en Europa. Samsung Bioepis ha venido trabajando para garantizar un…
Riassunto: Samsung Bioepis avvia la commercializzazione di BYOOVIZ®, biosimilare di Lucentis (ranibizumab), in Europa
INCHEON, Corea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. oggi ha annunciato che l’azienda ha avviato la commercializzazione diretta di BYOOVIZ®, un biosimilare di Lucentis1 (ranibizumab), in Europa. Samsung Bioepis si è impegnata per garantire il tra…
Samenvatting: Samsung Bioepis start met de verkoop in Europa van BYOOVIZ®, een biosimilar van Lucentis (ranibizumab)
INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. heeft vandaag bekendgemaakt dat het bedrijf is begonnen met de directe verkoop van BYOOVIZ®, een biosimilar van Lucentis1 (ranibizumab), in Europa. Samsung Bioepis heeft gewerkt aan een naadloz…
Samsung Bioepis commence la commercialisation de BYOOVIZ®, médicament biosimilaire du Lucentis (ranibizumab), en Europe
INCHEON, Corée–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. a annoncé aujourd’hui avoir commencé la commercialisation directe de BYOOVIZ®, un médicament biosimilaire du Lucentis1 (ranibizumab), en Europe. Samsung Bioepis s’est efforcé d’assurer un trans…
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously a…
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe
INCHEON, Korea–(BUSINESS WIRE)– #biosimilars–Samsung Bioepis announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe.